SFX by Ex Libris Inc.

Title:	Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons
Source:	Nature [0028-0836] Huang, H S yr:2011

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Mabb, Angela M. "Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes." Trends in neurosciences 34.6 (2011): 293-303.
description	2.	Beaudet, Arthur L. "Angelman syndrome: Drugs to awaken a paternal gene." Nature 481.7380 (2011): 150-152.
description	3.	Bliss, T V V. "Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path." The Journal of physiology 232.2 (1973): 331-56.
description	4.	Su, H. "Mitochondrial dysfunction in CA1 hippocampal neurons of the UBE3A deficient mouse model for Angelman syndrome." Neuroscience Letters 487.2 (2009): 129-33.
description	5.	Peters, Sarika U. "Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid." American journal of medical genetics. Part A 152A.8 (2010): 1994-2001.
description	6.	Malenka, R C C. "An essential role for postsynaptic calmodulin and protein kinase activity in long-term potentiation." Nature 340.6234 (1989): 554-7.
description	7.	Clayton-Smith, J. "Angelman syndrome: a review of the clinical and genetic aspects." Journal of medical genetics 40.2 (2003): 87-95.
description	8.	Yaning Wu, Y. "A Drosophila model for Angelman syndrome." Proceedings of the National Academy of Sciences of the United States of America 105.34 (2008): 12399-12404.
description	9.	Collingridge, G L L. "Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus." The Journal of physiology 334.1 (1982): 33-46.
description	10.	Bliss, T V P. "A synaptic model of memory: long-term potentiation in the hippocampus." Nature 361.6407 (1993): 31-9.
description	11.	Groden, F. "NT5E Mutations and Arterial Calcifications." The New England journal of medicine 364.5 (2011): 432-442.
description	12.	Scheiffele, P. "NEUROSCIENCE Angelman syndrome connections." Nature 468.7326 (2010): 907-908.
description	13.	Buiting, K. "Prader-Willi syndrome and Angelman syndrome." American Journal of Medical Genetics. Part C, Seminars in Medical Genetics 154C.3 (2010): 365-376.
description	14.	Lynch, G S S. "Heterosynaptic depression: a postsynaptic correlate of long-term potentiation." Nature 266.5604 (1977): 737-9.
description	15.	Goldman, S. E. E. "Sleep in children and adolescents with Angelman syndrome : association with parent sleep and stress." JIDR. Journal of intellectual disability research 56.2 (2011): 600-608.
description	16.	Cooke, T. "Plasticity in the human central nervous system." Brain 129.7 (2006): 1659-1673.
description	17.	Pi, Hyun J. "Autonomous CaMKII can promote either long-term potentiation or long-term depression, depending on the state of T305/T306 phosphorylation." The Journal of neuroscience 30.26 (2010): 8704-8709.
description	18.	Sears LL, L L L. "Abnormal classical eye-blink conditioning in autism." Journal of Autism and Developmental Disorders 24.6 (1994): 737-51.
description	19.	Summers, J. "Using Discrete Trial Instruction to Teach Children with Angelman Syndrome." Focus on Autism and Other Developmental Disabilities 24.4 (2009): 216-226.
description	20.	Grieco, Joseph C. "An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome." BMC neurology 14.1 (2014): 232-232.